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Abstract
microRNAs (miRNAs) are a class of regulatory small non-coding molecules that control gene expression at post-
transcriptional level. Deregulation of miRNA functions affects a variety of biological processes also involved in the etiology
of several human mendelian and complex diseases. Recently, aberrant miRNA expression has been observed in Cystic
Fibrosis (CF), an autosomal-recessive genetic disorder caused by mutations in the CFTR gene, in which a genotype-
phenotype correlation is not always found. In order to determine miRNA role in CFTR post-transcriptional regulation, we
searched for miR-responsive elements in the CFTR 39-UTR. In silico analysis, performed using different computational on-line
programs, identified some putative miRNAs. Both miR-101 and miR-494 synthetic mimics significantly inhibited the
expression of a reporter construct containing the 39-UTR of CFTR in luciferase assays. Interestingly, miR-101/miR-494
combination was able to markedly suppress CFTR activity by approximately 80% (p,0.001). This is one of the first in vitro
studies implicating microRNAs as negative regulators of the CFTR gene expression. miRNA aberrant expression and function
might explain the wide phenotypic variability observed among CF patients.
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Introduction
Cystic Fibrosis (CF) is a common monogenic disease caused by
mutations in the Cystic Fibrosis Transmembrane conductance Regulator
(CFTR) gene coding for an ATP-dependent anion channel-protein
required to regulate sweat, digestive juices and mucus components
[1]. Even if CF is inherited as a recessive trait, with more than 1500
causative mutations, a wide range of inter- and intra-familial
variability is reported so that individuals with the same genotype
may show different phenotypes. Therefore, the clinical phenotype is
not entirely due to the CFTR mutant homozygous or compound
heterozygous status but genetic modifiers and environmental factors
are likely to modulate the severity of the disease [2,3]. Recent papers
focused on the possible role of microRNAs in the inter- and intra-
familial variability of the CF clinical manifestations [4]. MicroRNAs
are evolutionarily conserved, small non-coding RNAs that negatively
regulate gene expression at the post-transcriptional level by either
repressing translation or decreasing mRNA stability [5,6]. Mature
miRNA, a single-stranded RNA with a length of about 22
nucleotides, is incorporated into a RNA-induced silencing complex
(RISC) and is ableto bind target transcripts through base pairing with
their 39-untranslated regions (UTRs). The main sequence for mRNA
recognition encompasses bases 2 to 8 at the 59-end of the mature
miRNA and it is known as the ‘‘seed sequence’’ [7,8]. To date, more
than 800 miRNAs have been computationally identified in the
human genome [9,10], each one having the potentialcapacity to bind
to hundreds of transcripts, and the biological functions of most
miRNAs are rapidly emerging. As estimated by in silico prediction
algorithms [10,11], miRNAs regulate at least 30% of the protein-
encoding genes and are involved in a broad range of cellular
processes such as proliferation, differentiation, homeostasis and
apoptosis. It is therefore predictable that the dysregulation of the
miRNA pathway might contribute to human diseases, including
mendelian disorders as demonstrated for Atassia telangectasia,
Fragile X syndrome and Huntington’s disease [12]. Emerging
evidence suggests that changes in expression of microRNAs are
associated with Cystic Fibrosis [4,13–15]. In a recent work, Oglesby
et al. [13] performed a miRNA profile screening in bronchial
brushings from CF individuals versus non-CF controls and showed
that miR-126 was specifically down-regulated in CF airway epithelial
cells and targeted TOM1 gene transcripts. In the present work, we
address the role of miRNAs in the post-transcriptional regulation of
the CFTR gene. In particular,after the insilico identification of a list of
putative miRNAs able to target CFTR mRNA, we demonstrated by
in vitro analysis that miR-101 and miR-494 were able to markedly
suppress CFTR expression either alone and in combination.
Materials and Methods
Bioinformatic analysis
UCSC (http://genome.ucsc.edu/, hg19 assembly), NCBI
(http://www.ncbi.nlm.nih.gov/) and UTRdb (http://utrdb.ba.itb.
cnr.it/) genome browsers provided information of human CFTR
gene(NM_000492.3;3HSAR032708).Computationalidentification
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commonprediction algorithmsTargetScan (http://www.targetscan.
org, release 5.1), PicTar (http://pictar.mdc-berlin.de/), miRBase
(http://microrna.sanger.ac.uk, release 13.0), miRanda (http://www.
microrna.org), EIMMo (http://www.mirz.unibas.ch/ElMMo2/)
and miRDB (http://mirdb.org/miRDB/). For most programs,
standard parameter settings were used. Seeds wereusually considered
of 6–8 bases in length, beginning at position 2 at 59-end of the
microRNA, with no mismatches or loops allowed; a single G:U
wobble was acceptable only in 7- or 8-mers. We also used the
meta-server miRecords (http://mirecords.biolead.org/) that inte-
grates the predicted targets of the following miRNA target prediction
tools: DIANA-microT, MicroInspector, miRanda, MirTarget2,
miTarget, NBmiRTar, PicTar, PITA, RNA22, RNAhybrid, and
TargetScan/TargertScanS [16]. Secondary structure and mean
free energy (mfe) of the miRNA:mRNA hybrid were obtained
byRNAHybrid(http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/)
and rna22 (http://cbcsrv.watson.ibm.com/rna22.html web servers.
Furthermore, miRNA information and expression profiles, such as
quantities and tissue specificity from microarray and quantitative
real-time polymerase chain reaction experiments, were obtained
by miRBase (http://www.mirbase.org/), miRNAMap 2.0 (http://
mirnamap.mbc.nctu.edu.tw/), and miRanda [17] database interro-
gation.
Luciferase reporter plasmid construction
The 39-UTR region of CFTR (813–1553 bp of 3HSAR032708)
containing the predicted target sites of miR-101 and miR-494 was
amplified from human genomic DNA using a proof reading Phusion
High-Fidelity PCR master mix (Finnzymes,Espoo,Finland) with the
following primers CFTR 39UTR-F 59-GCTCTAGAAGACCTTT-
GAACTAGAGTTTAGC-39 and CFTR 39UTR-R 59-GCTCTA-
GAACACAAATGTATGGATTTTATTG -39. The amplified 741-
bp product was inserted into the XbaI site (underlined primer
sequences) of the pRLTK vector (Promega) immediately downstream
of the luciferase gene. Transformants were validated by specific
restriction digestions and direct sequencing. The luciferase reporter
construct was termed pCFTR-39UTR. The CFTR luciferase vectors
with mutated target sites for miR-101 or miR-494 (pCFTR-39UTR-
mut101 and pCFTR-39UTR-mut494, respectively) were generated
using the Quickchange II Site-directed mutagenesis kit (Stratagene,
Foster City, CA) and synthetic oligonucleotides (Sigma-Aldrich):
mut101-F 59-CTGACTCTTAAGAAGACTGCATTATATTT-




TG-39 and mut494-R 59-CAGCATTGTTATATATGTTCGTAA-
GTTTATTAAAATAAATATTTCCTAGAG-39.
Cell culture
Human embryonic kidney 293 (HEK293) cells, purchased from
ATCC (Manassas, VA), were cultured in DMEM (Gibco, Carlsbad,
CA) supplemented with 10% fetal bovine serum, 1% non-essential
aminoacid solution, 1% L-glutamine and 2% penicillin/streptomy-
cin. Cells were incubated at 37uC and 5% CO2.
Transfection of microRNAs and reporter plasmids for
luciferase assays
HEK293 were plated at a density of 3610
5 per well in 24-well
plates and transiently transfected after 4–5 hours with 50 ng of
Renilla luciferase expression constructs (pRLTK, pCFTR-3’UTR,
pCFTR-3’UTR-mut101 or pCFTR-39UTR-mut494), 12.5 ng of
reference Firefly luciferase reporter (pGL3-SV40, Promega) and
miRNA duplexes at 100 nM final concentration (hsa-mir-101
miRIDIAN Mimics MI0000739/MIMAT0000099, hsa-mir-494
miRIDIAN MimicsMI0003134/MIMAT0002816, miRIDIAN
microRNA Mimic Negative Control #1, Dharmacon, Inc.
Chicago, IL) using 1.5 ml of Lipofectamine 2000 (Invitrogen) in
OptiMEM reduced serum media (Invitrogen) in accordance with
the recommended conditions. Cells were lysed 48 h after transfec-
tion and luciferase assays were performed using the Dual Luciferase
Reporter Assay System (Promega) following the manufacturer9s
protocol. Renilla luciferase activity was normalized to the Firefly
luciferase activity for each reaction. The experiments were carried
outatleastthree times,each intriplicate.Alltheluciferasedatawere
expressed as the mean 6 standard error (SE) normalized to the
negative control miRNA for the same reporter construct.
Statistical analysis
Statistical significance of the comparison between two or
multiple treatments was derived from one-way analysis of variance
(ANOVA) for independent samples with Bonferroni post-test using
GraphPad software. Differences were considered significant if the
probability (p) was ,0.05. The number of asterisks indicates the p-
value (*, p,0.05; **, p,0.01; *** p,0.001).
Results
Computational prediction of microRNA responsive elements
(MREs)withinthe 39-UTRofCFTRtranscript wasperformedusing
commonly prediction programs such as TargetScan, PicTar, and
miRanda. These web servers use complicated algorithms searching
for target sequences with perfect or nearly perfect pairing to the 39-
UTR sequence, evaluating the thermodynamic stability of miRNA-
mRNA hybrids and performing comparative sequence analysis to
check evolutionary conservation. Also, the 39 pairing contribution,
the local AU content and the distance to the nearest end of the
annotated UTR were scored. Since various programs might predict
different microRNAs for a given coding gene, we also used the
‘‘Predicted Targets’’ section of miRecords which gave a global view
of our analyses as this meta-server integrates predicted miRNA
targets produced by 11 established miRNA target prediction
programs. Overall, we registered 496 putative CFTR targeting
miRNAs. Three hits were predicted by five single programs and 20
hits by four target prediction softwares. The most likely candidate
miRNAs targeting the CFTR 3’UTR which overlapped in at least
three prediction programs resulted miR-101, miR-144, miR-199-
3p, miR-345, miR-376b, miR-377, miR-380, miR-494, miR-509-
3p,miR-600andmiR-645.Wecombined alltheseinformationwith
thermodynamic and on-line available expression data and, finally,
we selected miR-101 and miR-494 microRNAs as the more likely
regulators of the CFTR mRNA. Notably, these miRNAs looked up-
regulatedinthe miRNAexpressionprofile analysisperformedinthe
CF bronchial brushings in comparison to healthy controls [13].
Both miR-101 and miR-494 are conserved in Homo sapiens, Macaca
mulatta and Mus musculus and each miRNA sequence has a single
putative target site within the CFTR 3’UTR at position 1508–1514
and 1140–1147, respectively (Figure 1A). In particular, miR-101
responsive element is a 7mer-A1 having an exact match to positions
2–7 of the miRNA (the seed) and an immediate downstream ’A’
which is across from microRNA nucleotide 1 while miR-494 target
site is a 8-mer element that shares an exact complementarity
to position 2–8 of the mature microRNA followed by an ’A’. The
miR-101:CFTR mRNA heteroduplex displayed a mfe value of
214.2 kcal/mol whereas miR-494:CFTR hybrid structure showed
a 213.5 kcal/mol value (Figure 1B).
MicroRNAs Control CFTR Gene Expression
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CFTR, HEK293 cells were co-transfected either with a reporter
construct containing 741 base pairs of the human CFTR 3’UTR
downstream of the Renilla luciferase open reading frame (Figure 2A)
or with a control Renilla plasmid together with either a synthetic
microRNA mimics (miR-101 or miR-494) or the negative control
microRNA (miR-Ctr). Both miR-101 and miR-494 significantly
suppressed luciferase expression compared to control microRNA with
a corresponding decrease of about 40% (p,0.01) and 60% (p,0.001)
as shown in Figure 2B. miR-494 was also able to inhibit pCFTR-
3’UTR in a dose-dependent manner and at low doses since the Renilla
activity was significantly reduced of about 30% using a 10 nM miR-
concentration (Figure S1). Notably, when miR-101 and miR-494 were
co-overexpressed, a synergistic effect between miRNAs was observed,
as highlighted by the strong reduction of the pCFTR-3’UTR reporter
activity of approximately 80% (p,0.001). No significant decrease was
evident when HEK293 cells were transfected with a double dose of
microRNA negative control (Figure 2C). The MRE specificity in the
CFTR 3’UTR was evaluated by site-directed mutagenesis of the
nucleotides at positions 3, 4, 6, 7 of the miR-101 seed sequence
(TACTGTA to TAGAGAT) and at position 2, 3, 6, 8 of the miR-494
target site (ATGTTTCA to AACTTACG) (Figure 3A). No repression
was observed with pCFTR-3’UTR constructs in which the putative
miRNA-binding sites for miR-101 or miR-494 were altered
(Figure 3B). In particular, the activity of the reporter construct
mutated at the specific miR-101 seed (pCFTR-3’UTR-mut101) was
unaffected by the concomitant transfection of miR-101 and led to a
significant decreased luciferase value only with miR-494 over-
expression (p,0.001). At the same time, pCFTR-3’UTR-mut494
reporter activity was significantly reduced by miR-101 (p,0.05) while
miR-494 transfection was nearly inactive. These data suggest that
modifications of the specific miRNA binding-sites in the CFTR 3’UTR
are able to reduce the inhibitory function of miR-101 and miR-494
(Figure 3B). Thus,miR-101 and miR-494 functionallyinteract with the
CFTR 3’-UTR and suppress the corresponding protein product.
Discussion
Since aberrant level and function of microRNAs have been
recently observed in Cystic Fibrosis tissues [13-15,18], the
possibility they may act as phenotype modifiers was raised. Our
data, together with the very recent publication by Gillen et al.,
[18] support a role of some microRNAs in the post-transcriptional
regulation of the CFTR channel synthesis. The CFTR mRNA 3’-
UTR, the putative site of miRNA annealing, is highly conserved in
different species and contains several regulatory motifs important
Figure 1. Bioinformatic prediction of microRNAs potentially targeting the CFTR gene. (A) Schematic representation of the CFTR 3’UTR and
miRNAs (triangles). Ribonucleotide sequences of the putative miR-101 and miR-494 responsive elements in aligned human, rhesus and mouse CFTR
3’UTRs paired with the mature human miR-sequence (from TargetScan 5.1 database). Numbers indicate the predicted miR-101 and miR-494 seed
sequences (in bold) using the numbering of the human CFTR 3’UTR (3HSAR032708 from UTRdb database). (B) Predicted CFTR 3’UTR hybrid structure
with miR-101 or miR-494 and mean free energy (mfe) obtained by RNAHybrid server.
doi:10.1371/journal.pone.0026601.g001
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a few miRNA-3’-UTR possible pairing with similar expression
profiles and selected miR-101 and miR-494 for further analysis,
since they showed the best possibility of positive interaction.
Luciferase in vitro experiments confirmed that both miR-101 and
miR-494 targeted and functionally suppressed CFTR construct
mRNA translation with a moderate and strong action, respective-
ly, and this activity was almost lost after mutation of the putative 3’
UTR target-sites. The different strength of the luciferase
repression could be due to the secondary structure MRE
accessibility, the relative position of the specific target sites in the
CFTR 3’-UTR as well as the different seed match types.
Furthermore, miR-101 and miR-494 seem to act synergistically
on CFTR-reporter inhibition with a more than additive effect on
the post-translational control and this could have a physiological
relevance in the complex disease phenotypes observed in CF.
Interestingly, our results are corroborated by expression profiling
experiments of different human miRNAs from CF patients airway
epithelial samples in which both miR-101 and miR-494 looked up-
regulated (Relative Quantification $1.5) compared to non-CF
individuals confirming an inverse correlation with CFTR levels
[13]. In particular, miR-494 levels were altered in four of the five
CF samples showing an up to 6-fold increase respect to normal
airway brushings. Up-regulation of miR-494 in asthmatic samples
[20] and direct influence in cell cycle progression of primary
murine bronchial epithelial cells exposed to carcinogens [21,22]
suggest that miR-494 altered levels have effects mainly in the lung
compartment. As far as mir-101 concerns, recent evidences under-
line its role in the biosynthesis of pro-inflammatory cytokines [23]
and its function in central nervous system [24] providing a possible
explanation for both lung excessive inflammation and neural
symptoms observed in CF patients [25]. Our study shows the
possible relevance of miRNA pathways as genetic modifiers that
may contribute to the varied CF phenotypes seen even among
individuals carrying the same CFTR gene mutations. We speculate
that microRNAs are largely responsible for how badly the illness
affects patients since even minimal alterations in miR-101 and/or
miR-494 levels could negatively influence the stability of the CFTR
transcript which in turn might have an effect on the amount and
maturation of CFTR protein and so on the degree of CF severity.
Figure 2. Mir-101 and mir-494 target the CFTR 3’-UTR. (A) Schematic representation of the construct used in the luciferase assays. A fragment
of 741 bp of the CFTR 3’-UTR, encompassing the putative responsive elements for miR-101 and miR-494, was cloned in pRLTK vector downstream to
the Renilla luciferase coding sequence. (B) HEK293 cells were transfected independently with pRLTK control plasmid or pCFTR-3’UTR vector together
with either specific microRNA (miR-101 or miR-494) or a negative control miRNA (miR-Ctr). At 48 hour post-transfection, luciferase activity was
measured and normalized to the Firefly control. Data are presented as the normalized activity of the indicated miR-transfected cells relative to the
negative mimic control (miR-Ctr). These results represent the mean of at least three independent experiments 6 standard error (SE), each carried out
in triplicate. The significance levels were obtained by ANOVA: **, p,0.01; ***, p,0.001 compared with the control miRNA. (C) Combined miR-101/
miR-494 synthetic mimics (100 nM miR-101 and 100 nM miR-494) or 200 nM miR-Ctr (
1) were delivered into HEK293 cells together with pCFTR-3’UTR
plasmid. Luciferase activity measured and data reported as in B. Statistical significance from ANOVA: ns, not significant; **, p,0.01; ***p,0.001
compared with the control miRNA; miR-101+miR494 versus miR-Ctr either at 100 nM or at 200 nM.
doi:10.1371/journal.pone.0026601.g002
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decreased activity and the concerted inhibitory interaction with
CFTR 39-UTR sequence showed in our in vitro results. Recent
evidences also suggest that RNA binding proteins and microRNAs
can regulate transcripts involved in a common pathway [26]. In
particular, Spence [19] identified conserved regulatory motifs in
the CFTR 3’-UTR that had a partial identity with 3’-UTR of
SEC24, a gene coding for a protein implicated in the CFTR
translocation out of the endoplasmic reticulum. Our preliminary in
silico analysis found that both miR-101 and miR-494 may target
SEC24 3’-UTR and two other genes, TGFB1 and MBL2, which
are known to modify the development and/or the severity of lung
disease in CF [2], suggesting the existence of a coordinated
network of gene expression control by microRNAs. Therefore,
alteration of miR-101 and/or miR-494 levels in CF patients could
influence the disease clinical expression with particular implica-
tions in CF lung function, such as increased susceptibility to
infections, chronic airways inflammation and response to specific
therapies. These miRNAs, as CF genetic modifiers, might act
either by directly influence CFTR gene expression or/and other
functionally related genes. Future investigations will be addressed
to confirm this hypothesis such as the characterization of the entire
CFTR 3’-UTR in a panel of CF subjects carrying the same
mutations and different clinical phenotype looking for sequence
variants in the miR-responsive elements that could dramatically
alter CFTR regulation as well as mutations in the miR-101 and
miR-494 genes which could explain their altered expression.
In conclusion, the discovery of miRNAs directly controlling
CFTR regulation could have an enormous impact in the elucidation
of CF pathology and might also contribute to clarify the biological
causes of the phenotype/genotype discrepancies observed among
CF patients. In addition, miR-based diagnostic and therapeutic
applications represent an exciting possibility for this common
mendelian disease. As for Duchenne muscular dystrophy [27,28],
quantification of selected miRNAs might be used as a sensitive
biomarker tool of CF severity and functional suppression of CFTR-
targeting miRNAs, such as miR-101 and/or miR-494, could prove
a strategy to efficiently restore CFTR synthesis in patients carrying
mutations leading to insufficient protein expression.
Supporting Information
Figure S1 Dose-dependent miR-inhibition of the CFTR
luciferase reporter. Levels of luciferase activity in HEK293 cells
Figure 3. Specificity of miR-101 and miR-494 CFTR suppression by recognition of the seed sequence. (A) Schematic representation of the
reporter constructs carrying CFTR 3’UTR mutated at miR-101 responsive element or mir-494 seed sequence. (B) Relative luciferase activity in HEK293
cells over-expressing the indicated miRNAs and transfected with the CFTR wild-type 3’UTR vector or its mutant derivative pCFTR-3’UTR-mut101 and
pCFTR-3’UTR-mut494. Data are presented as the normalized activity of miR-transfected cells (miR-101 or miR-494) relative to cells transfected with
miR-Ctr. All data are average values 6 SE from at least three experiments (ANOVA, ns, not significant; *, p,0.05; ***, p,0.001 compared to the basal
value with miR-Ctr).
doi:10.1371/journal.pone.0026601.g003
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with the CFTR w i l d - t y p e3 ’ - U T Rv e c t o r .m i R - 4 9 4w a sa b l et o
significantly inhibit the reporter activity in a dose-dependent manner
and at low concentrations. All data are average values 6SE from three
independent experiments, each carried out in triplicate. Statistical
comparisons were performed by ANOVA (ns, not significant;
*, p,0.05; **, p,0.01; ***, p,0.001 compared to the basal value).
(TIF)
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